Shares in Novo Nordisk fell as much as 3% on Friday after the Danish drugmaker and U.S. rival Eli Lilly agreed with the U.S.
Amid rising climate tensions, many people around the world are running projects to combat rising CO2 emissions and help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback